Preview

Гормон роста и сердечно-сосудистая система

https://doi.org/10.14341/probl201157437-47

Аннотация

В последние годы выяснилось, что гормон роста (ГР) не только регулирует соматический рост, но и обладает многочисленными другими эфектами. В частности, ГР прямо и через сложную систему инсулиноподобного фактора роста-1 (ИФР-1) и ИФР-связывающих белков (ИФРСБ) участвует в поддержании структуры и функции сердца [1, 2]. В обзоре рассматриваются современные представления о влиянии дефицита и избытка ГР на сердечно-сосудистую систему (ССС).

Об авторе

N Volevodz



Список литературы

1. Lombardi G., Colao A., Cuocolo A. et al. Cardiological aspects of growth hormone and insulin-like factor-1. J Pediatr Endocrinol Metab 1997; 10: 553-560.

2. Sacca L., Cittadini A., Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15:555-573.

3. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovascular Research 1995; 30: 825-834.

4. Sklar M.M., Kiess W., Thomas C.L., Nissley S.P. Developmental expression of the tissue insulin-like growth factor-II/ mannose 6-phosphate receptor in the rat. J Biol Chem 1989; 264: 16733-16738.

5. Isgaard J., Wahlander H., Adams M.A., Friberg P. Increased expresiion of growth receptor mRNA and insulin-like growth factor-I mRNA in volume overloaded hearts. Hypertension 1994; 23: 884-888.

6. Wahlander H., Isgaard J., Jenische E., Friberg P. Left ventricular insulin-like growth factor-I increases in early renal hypertension. Hypertension 1992; 19: 25-32.

7. Hanson M.C., Kenneth A.F., Alexander R.V., Delafontaine P. Induction of cardiac insulin-like growth factor-I gene expression in pressure overload hypertrophy. Am J Med Sci 1993; 306: 69-74.

8. Neri Serneri G.G., Modesti P.A., Boddi M. и др. Cardiac growth factors in human hypertrophy: relations with myocardial contractility and wall stress. Circ Res 1999; 85: 57-67.

9. Cittadini A., Ishiguro Y., Strömer H. et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circulation Research 1998; 83: 50-59.

10. Freestone N.S., Ribaric S., Mason W.T. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Molecular and Cellular Biochemistry 1996; 163: 223-229.

11. Ito H., Hiroe M., Hirata Y. et al. Insulin-like growth factor-I induces hypertrophy with enchanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-1721.

12. Cittadini A., Stromer H., Katz S.E. et al. Differential cardiac effects of growth-hormone and insulin-like growthn factor-I in the rat: a combined in vivo and in vitro evaluation. Circulation 1996; 93: 800-809.

13. Duerr R.L., Huang S., Miraliakbar H.R. et al. Insulin-like growth factor-I enchances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-627.

14. Duerr R.L., McKirnan D., Gim R.D. et al. Cardiovascular effects of insulin-like growth factor-I and growth hormone in chronic left ventricular failure in the rat. Circulation 1996; 93: 2188-2196.

15. Caidahl K., Eden S., Bengtsson B.-A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393-400.

16. Cittadini A., Ehrnborg C., Longobardi S. et al. Growth hormone activates cardiac growth in normal subjects: a multicenter, double-blind, placebo-controlled study. Endocrine Society's 81st Annual Meeting. June 12-15, 1999; San Diego, California OR4-OR 2.

17. Vetter U., Kupferschmid C., Lang D., Pentz S. Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Bas Res Cardiol 1988; 83: 647-654.

18. Ren J., Sowers J.R., Natavio M., Brown R.A. Influence of age on inotropic response to insulin and insulin-like growth factor-I in spontaneously hypertensive rats: role of nitric oxide. Proc Soc Exp Biol Med 1999; 221: 46-52.

19. Ren J., Walsh M.F., Hamaty M. et al. Altered inotropic response to IGF-I in diabetic rat heart:influence of intracellular Ca 2+ and NO. Am J Physiol 1998; 275: 823-830.

20. Kinugawa S., Tsutsui H., Ide T. et al. Positive inotropic effect of IGF-I on nrmal and failing cardiac myocytes. Cardiovascular Research 1999; 43: 157-164.

21. Tsukahara H., Gordienko D.V., Tonhoff B. et al. Direct demonstration of insulin-like growth factor-I insuced nitric oxide production by endothelial cells. Kidney Int 1994; 45: 598-604.

22. Fryburg D.A. N-monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF-I. Possible role of nitric oxide in muscle protein synthesis. J Clin Invest 1996; 97: 1319-1328.

23. Delafontaine P. Growth factors and fascular smooth muscle cell growth responses. Eur Heart J 1998; 19: 18-22.

24. Timsit J., Riou B., Bertherat J. et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pettern, and myosin adenosinetriphophatase activity of rat left vantricle. J Clin Invest 1990; 86: 507-515.

25. Thuesen L., Christiansen J.S., Sorensen K.E. et al. Incresed myocardial contractility following growth hormone administration in normal man. An echocardiographic study. Danish Med Bull 1988; 35: 193-196.

26. Erfurth E.M., Hagmar L. Cardiovascular mortality among pituitary insufficient patients. Clinical Endocrinology 1998; 49: 271-272.

27. Tomlinson J.W., Holden N., Hills Wheatley R.K. et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425-431.

28. McCallum R.W., Petrie J.R., Dominiczak A.F., Connell J.M.C. Growth hormone deficiency and vascular risk. Clinical Endocrinology 2002; 57: 11-24.

29. Colao A., Di Somma C., Savanelli M.C. et al. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Hormone IGF Research 2006; 16: Suppl A: 41-48.

30. Colao A., Cuocolo A., Marzullo P. et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1999; 84: 17-23.

31. De Boer H., Blok G.J., Voerman H.J. et al. Serum lipid levels in growth hormone-deficient men. Metabolism 1994; 43: 199-203.

32. Sanmarti A., Lucas A., Hawkins F. et al. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socioeconomic impact and health status. European Journal of Endocrinology 1999; 141: 481-489.

33. Sverrisdottir Y.B., Elam M., Herlitz H. et al. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1998; 83: 1881-1885.

34. Colao A., Marzullo P., Di Somma C., Lombardi G. Growth hormone and the heart. Clin Endocrinol 2001; 54: 137-154.

35. Безлепкина О.Б. Синдром гипофизарной карликовости у взрослых: диагностика, клиники, медико-социальная реабилитация: Автореф. дис. … д-ра мед. наук. М 2004.

36. Colao A., Di Somma C., Salerno M. et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002; 87: 8: 3650-3655.

37. Merola B., Cittadini A., Colao A. et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1993; 77: 1658-1661.

38. Shulman D.I., Root A.W., Diamond F.B. et al. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. Journal of Clinical Endocrinology and Metabolism 2003; 88: 4095-4099.

39. Salerno M., Esposito V., Spinelli L. et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clinical Endocrinology 2004; 60: 630-636.

40. Thuesen L., Jorgensen J.O.L., Muller J.R. et al. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clinical Endocrinology 1994; 41: 615-650.

41. Valcavi R., Gaddi O., Zini M. et al. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995; 80: 659-666.

42. Colao A., Spinelli L., Cuocolo A. et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin l Endocrinol Metab 2002; 87: 3097-3104.

43. Волеводз Н.Н. Системные и метаболические эффекты гормона роста у детей с различными вариантами низкорослости: Автореф. дис. … д-ра мед. наук. М 2005; 43.

44. Volevodz N.N., Peterkova V.A. Cardiac structure, systolic function and serum lipid levels in children with growth hormone deficiency before and during growth hormone therapy. Horm Res 2004; 62: Suppl 2: 2004.

45. Stamoyannou L., Georgacopoulos D., Trapali C. et al. M-mode echocardiographic evaluation of systolic function, LV volume and mass in children on growth hormone therapy. J Pediatr Endocrinol Metab 2000; 13: 157-161.

46. Colao A., Spiezia S., Cerbone G. et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology 2001; 54: 515-524.

47. Markussis V., Beshyah S.A., Fisher C. et al. Detection of premature atherosclerosis by high resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188-1192.

48. Colao A., Cuocolo A., Di Somma C. et al. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clinical Endocrinology 2000; 52: 447-455.

49. Colao A., Di Somma C., Cuocolo A. et al. The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. Journal of Clinical Endocrinology and Metabolism 2004; 89: 5908-6004.

50. Jorgensen J.O., Pedersen S.A., Thuesen L. et al. Effects of growth hormone therapy to GH deficient adults on bodu composition, muscle strength, exercise capacity and cardiac and renal eunction. A double-blind crossover study. Lancet 1989; 1: 1221-1225.

51. Lehmann E.D., Hopkins K.D., Weissberger A.J. et al. Aortic distensibility in growth hormone deficient adults. Lancet 1993; 341: 309 (letter).

52. Evans L.M., Davies J.S., Goodfellow J. et al. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clinical Endocrinology 1999; 50: 457-464.

53. Colao A., Marzullo P., Di Somma C., Lombardi G. Growth Hormone and the heart. Clinical Endocrinology 2001; 54: 137-154.

54. Maison P., Griffin S., Nicoue-Beglah M. et al. Impact of Growth Hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trias. Journal of Clinical Endocrinology and Metabolism 2004; 89: 2192-2199.

55. Cuneo R.C., Salomon F., Wilmshurst P. et al. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clinical Science 1991; 81: 587-592.

56. Beshyah S.A., Shahi M., Foale R., Johnston D.G. Cardiovascular effects of prolonged growth hormone replacement in adults. Journal of Internal Medicine 1995; 237: 35-42.

57. Sartorio A., Ferrero S., Conti A. et al. Adults with childhood-onset growth hormone deficiency: effects of growth hormone treatment on cardiac structure. Journal of Internal Medicine 1997; 241: 515-520.

58. Link K., Bulow B., Westman K. et al. Low individualized growth hormone (GH) dose increased renal and cardiac growth in young adults with childhood onset GH deficiency. Clinical Endocrinology 2001; 55: 741-748.

59. Salerno M., Esposito V., Farina V. et al. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. Journal of Clinical Endocrinology and Metabolism 2006; 91: 1288-1295.

60. Amato G., Carella C., Fazio S. et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. Journal of Clinical Endocrinology and Metabolism 1993; 77: 1671-1676.

61. Ter Maaten J., De Boer H., Kamp O. et al. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 1999; 84: 2373-2380.

62. Nass R., Huber R.M., Klauss V. et al. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. Journal of Clinical Endocrinology and Metabolism 1995; 80: 552-557.

63. Gibney J., Wallace J.D., Spinks T. et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 1999; 84: 2596-2602.

64. Gillberg P., Bramnert M., Thorén M. et al. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Hormone and IGF Research 2001; 11: 273-281.

65. Colao A., Di Somma C., Cuocolo A. et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001; 86: 1874-1881.

66. Colao A., Di Somma C., Pivonello R. et al. The cardiovascular risk of adult growth hormone (GH) deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12 month prospective study. Journal of Clinical Endocrinology and Metabolism 2002; 87: 1088-1093.

67. Chrisoulidou A., Beshyah S.A., Rutherford O. et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 2000; 85: 3762-3769.

68. Ezzat S., Fear S., Gaillard R.C. et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. Journal Clinical Endocrinology & Metabolism 2002; 87: 2725-2733.

69. Sas T.C., Cromme-Dijkhuis A.H., de Muinck Keizer-Schrama S.M. et al. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. J Pediatr 1999; 135: 470-476.

70. Beshyah S.A., Johnston D.G. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol 1999; 50: 1-15.

71. Colao A., Di Somma C., Filippella M. et al. Insulin-like growth factor-I deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clinical Endocrinology 2004; 61: 360-366.

72. Colao A., Di Somma C., Rota F. et al. Short-term effects of Growth Hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 2005; 90: 2056-2062.

73. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Review 2004; 25: 102-152.

74. Colao A., Marzullo P., Ferone D. et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR® in acromegaly. Journal of Clinical Endocrinology and Metabolism 2000; 86: 3132-3140.

75. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly epidemiology, pathogenesis and management. Endocr Rev 2004; 25: 102-152.

76. Colao A., Spinelli L., Marzullo P. et al. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case-control study. Journal of Clinical Endocrinology and Metabolism 2003; 88: 3196-3201.

77. Pereira A.M., van Thiel S.W., Lindner J.R. et al. Increased prevalence of regurgitation valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89: 71-75.

78. Herrmann B.L., Bruch C., Saller B. et al. Occurrence of left ventricular late potentials in patients active acromegaly. Clin Endocrinol 2001; 55: 201-207.

79. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89: 667-674.

80. Ferone D., Colao A., van der Lely A.J., Lamberts S.W. Pharmacology and surgery as primary therapy fpr acromegaly? Drugs Aging 2000; 17: 81-92.

81. Pereira J., Rodriguez-Puras M.J., Leal-Cerro A. et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 1991; 14: 17-23.

82. Hradec J., Kral J., Janota T. et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999; 83: 1506-1509.

83. Colao A., Cuocolo A., Marzullo P. et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 1999; 84: 1518-1523.

84. Lombardi G., Colao A., Marzullo P. et al. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotideinduced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002; 25: 971-976.

85. Baldelli R., Ferretti E., Jaffrain-Rea M.L. et al. Cardiac effects of lanreotide, a slow release somatostatin analog in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 1999; 84: 575-582.

86. Colao A., Cuocolo A., Marzullo P. et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001; 86: 1551-1557.

87. Colao A., Marzullo P., Ferone D. et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LARw in acromegaly. J Clin Endocrinol Metab 2000; 86: 3132-3140.

88. Colao A., Marzullo P., Cuocolo A. et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol 2003; 58: 169-176.

89. Herrington A.M., George K.W., Moulds C.C. Octreotide-induced bradycardia. Pharmacotherapy 1998; 18: 413-416.

90. Bihan H., Espinosa C., Valdes-Socin H. et al. Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. J Clin Endocrinol Metab 2004; 89: 11: 5308-5313.


Для цитирования:


. Гормон роста и сердечно-сосудистая система. Проблемы Эндокринологии. 2011;57(4):37-47. https://doi.org/10.14341/probl201157437-47

For citation:


Volevodz N.N. Growth hormone and the cardiovascular system. Problems of Endocrinology. 2011;57(4):37-47. (In Russ.) https://doi.org/10.14341/probl201157437-47

Просмотров: 58


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)